Article

Academy of Managed Care Compass: The Top 5 Strategic Priorities

Conference|AMCP: The Academy of Managed Care Pharmacy

Edith Rosato, RPh, IOM, the chief executive officer of the Academy of Managed Care Pharmacy, recently shared the organization's Top 5 strategic priorities for the coming year.

Edith Rosato, RPh, IOM, the chief executive officer of the Academy of Managed Care Pharmacy, recently shared the organization’s Top 5 strategic priorities for the coming year.

“Managed care pharmacy is widely understood and accepted as integral to the delivery of quality and affordable health care,” commented Edith Rosato, RPh, IOM, chief executive officer of the Academy of Managed Care Pharmacy (AMCP), prior to one of the general sessions at the AMCP Educational Conference 2012.

During the conference, Ms Rosato took to the stage before former US Senator Bill Bradley to share 5 strategic priorities she planned to address in the coming year in order to make AMCP the go-to organization for information:

  • Being the leading provider of education, research, and resources for managed care pharmacy
  • Expanding the value of membership
  • Improving patient outcomes and healthcare affordability
  • Being the authoritative voice for managed care pharmacy
  • Executing with organizational excellence

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Ashley Yocum
Lorna Warwick
Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia
Surbhi Sidana, MD, MBBS, Stanford University
Saad Z. Usmani, MD, MBA, FACP, FASCO, Memorial Sloan Kettering Cancer Center
EHA 2025 Congress Recap | Image Credit: Venngage
Lorna Warwick
Ashley Yocum, PhD
Dr Matthew Matasar
Dr Xavier Leleu
Related Content
Richard J. Nowak, MD, MS | Image Credit: Yale School of Medicine
June 24th 2025

Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS

Maggie L. Shaw Richard J. Nowak, MD, MS
In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Image of Managed Care Cast logo
August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw
At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com
June 18th 2025

Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

Rose McNulty
Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded comparable survival outcomes in a new study, challenging treatment norms.
Managed Care Cast.
June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia
On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
large B-cell lymphoma | Image credit: Cleveland Clinic
June 17th 2025

Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant

Mary Caffrey
Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell transplant or CAR T-cell therapy.
Chronic urticaria. | Image Credit: Cuoregentile - stock.adobe.com
June 16th 2025

Barzolvolimab Shows Long-Term Efficacy in Chronic Spontaneous Urticaria, Improving Patient Quality of Life

Cameron Santoro
New data shows that barzolvolimab offers sustained complete responses and significantly improved quality of life for patients with chronic spontaneous urticaria, with a favorable safety profile.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo